STOCK TITAN
  1. Home
  2. News
  3. ALPMY

Astellas Pharma Inc. - ALPMY STOCK NEWS

IMPACT
SENTIMENT
ALPMY : OTC
Astellas Provides Update on Fezolinetant New Drug Application in U.S.
IMPACT
SENTIMENT
ALPMY : OTC
Astellas Commits to Achieve Net Zero Greenhouse Gas Emissions by 2050
IMPACT
SENTIMENT
ALPMY : OTC
Astellas Announces Change of President and CEO and Management Structure
IMPACT
SENTIMENT
ALPMY : OTC
Astellas Transfers MYCAMINE® Product Worldwide
IMPACT
SENTIMENT
ALPMY : OTC
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease
clinical trial
IMPACT
SENTIMENT
ALPMY : OTC
Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers Symposium
conferences clinical trial
IMPACT
SENTIMENT
ALPMY : OTC
Astellas Receives SBTi Approval for Revised Science-Based Climate Goals to Reduce Greenhouse Gas Emissions
IMPACT
SENTIMENT
ALPMY : OTC SELB : Nasdaq
Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease
IMPACT
SENTIMENT
TWST : Nasdaq ALPMY : OTC
Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery Research Collaboration
IMPACT
SENTIMENT
SGEN : Nasdaq MRK : NYSE ALPMY : OTC
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Stock ALPMY logo
Astellas Pharma Inc.

OTC:ALPMY

ALPMY Rankings

#575 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ALPMY Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link
Pharmaceuticals: Other, Health Technology, Manufacturing, Medicinal and Botanical Manufacturing
Japan
Chuo Ku